Paper528273
The effect of time between X-irradiation and chemotherapy on the growth of three solid mouse tumors--I. Adriamycin.
Twentyman PR and 2 others. Int J Radiat Oncol Biol Phys, 1979. Cited by 56 papers, by iCite.
Cite this record
ConductScience Library. The effect of time between X-irradiation and chemotherapy on the growth of three solid mouse tumors--I. Adriamycin. Papers, record 528273. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/528273
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The effect of time between X-irradiation and chemotherapy on the growth of three solid mouse tumors--I. Adriamycin.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Doxorubicin | Major topic |
| Neoplasms, Experimental | Major topic |
| Animals | |
| Dose-Response Relationship, Radiation | |
| Female | |
| Mice | |
| Mice, Inbred Strains | |
| Sarcoma, Experimental | |
| Time Factors |
Source PubMed
Cited by21
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 56 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 7272187 | Enhancing effect of misonidazole on the response of the RIF-1 tumour to cyclophosphamide. | Br J Cancer | 1981 | https://conductscience.org/library/papers/7272187 | PubMed |
| 7150475 | Structure/activity relationships for the enhancement by electron-affinic drugs of the anti-tumour effect of CCNU. | Br J Cancer | 1982 | https://conductscience.org/library/papers/7150475 | PubMed |
| 7082556 | Effect of clinical levels of misonidazole on the response of tumour and normal tissues in the mouse to alkylating agents. | Br J Cancer | 1982 | https://conductscience.org/library/papers/7082556 | PubMed |
| 7073938 | Effect of misonidazole or metronidazole pretreatment on the response of the RIF-1 mouse sarcoma to melphalan, cyclophosphamide, chlorambucil and CCNU. | Br J Cancer | 1982 | https://conductscience.org/library/papers/7073938 | PubMed |
| 6871076 | Chemosensitization by lipophilic nitroimidazoles. | Br J Cancer | 1983 | https://conductscience.org/library/papers/6871076 | PubMed |
| 6849803 | Modification of CCNU pharmacokinetics by misonidazole--a major mechanism of chemosensitization in mice. | Br J Cancer | 1983 | https://conductscience.org/library/papers/6849803 | PubMed |
| 6824566 | An investigation of the possibility of chemosensitization by clinically achievable concentrations of misonidazole. | Br J Cancer | 1983 | https://conductscience.org/library/papers/6824566 | PubMed |
| 6758828 | Sensitivity of normal mouse marrow and RIF-1 tumour to hyperthermia combined with cyclophosphamide or BCNU: a lack of therapeutic gain. | Br J Cancer | 1982 | https://conductscience.org/library/papers/6758828 | PubMed |
| 6722006 | Misonidazole and CCNU: further evidence for a pharmacokinetic mechanism of chemosensitization and therapeutic gain. | Br J Cancer | 1984 | https://conductscience.org/library/papers/6722006 | PubMed |
| 6466544 | Enhancement of melphalan-induced tumour cell killing by misonidazole: an interaction of competing mechanisms. | Br J Cancer | 1984 | https://conductscience.org/library/papers/6466544 | PubMed |
| 6466543 | Preclinical pharmacokinetics of benznidazole. | Br J Cancer | 1984 | https://conductscience.org/library/papers/6466543 | PubMed |
| 6295428 | Modification by WR 2721 of the response to chemotherapy of tumours and normal tissues in the mouse. | Br J Cancer | 1983 | https://conductscience.org/library/papers/6295428 | PubMed |
| 6264941 | Modification of tumour and host response to cyclophosphamide by misonidazole and by WR 2721. | Br J Cancer | 1981 | https://conductscience.org/library/papers/6264941 | PubMed |
| 3966974 | Misonidazole protects mouse tumour and normal tissues from the toxicity of oral CCNU. | Br J Cancer | 1985 | https://conductscience.org/library/papers/3966974 | PubMed |
| 3940225 | CB 1954 revisited. II. Toxicity and antitumour activity. | Cancer Chemother Pharmacol | 1986 | https://conductscience.org/library/papers/3940225 | PubMed |
| 3940216 | CB 1954 revisited. I. Disposition kinetics and metabolism. | Cancer Chemother Pharmacol | 1986 | https://conductscience.org/library/papers/3940216 | PubMed |
| 3925974 | The effects of alpha and gamma interferons on human lung cancer cells grown in vitro or as xenografts in nude mice. | Br J Cancer | 1985 | https://conductscience.org/library/papers/3925974 | PubMed |
| 3698173 | Pharmacokinetic basis for the comparative antitumour activity and toxicity of chlorambucil, phenylacetic acid mustard and beta, beta-difluorochlorambucil (CB 7103) in mice. | Cancer Chemother Pharmacol | 1986 | https://conductscience.org/library/papers/3698173 | PubMed |
| 3606940 | The effects of whole body hyperthermia on the pharmacokinetics and toxicity of the basic 2-nitroimidazole radiosensitizer Ro 03-8799 in mice. | Br J Cancer | 1987 | https://conductscience.org/library/papers/3606940 | PubMed |
| 3168141 | Pharmacokinetics and metabolism of the mixed-function hypoxic cell sensitizer prototype RSU 1069 in mice. | Cancer Chemother Pharmacol | 1988 | https://conductscience.org/library/papers/3168141 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/528273
GET https://conductscience.org/api/papers/v1/528273/cited_by?page=2